These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 3103391)

  • 1. Fluctuation in response to chronic levodopa therapy: pathogenetic and therapeutic considerations.
    Chase TN; Juncos J; Serrati C; Fabbrini G; Bruno G
    Adv Neurol; 1987; 45():477-80. PubMed ID: 3103391
    [No Abstract]   [Full Text] [Related]  

  • 2. The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: the mechanism of action in the treatment of parkinsonism.
    Nutt JG; Woodward WR; Anderson JL
    Ann Neurol; 1985 Nov; 18(5):537-43. PubMed ID: 4073849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease.
    Fabbrini G; Juncos J; Mouradian MM; Serrati C; Chase TN
    Ann Neurol; 1987 Apr; 21(4):370-6. PubMed ID: 3579222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 3-O-methyldopa and the response to levodopa in Parkinson's disease.
    Nutt JG; Woodward WR; Gancher ST; Merrick D
    Ann Neurol; 1987 Jun; 21(6):584-8. PubMed ID: 3606046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy.
    Marsden CD; Parkes JD
    Lancet; 1976 Feb; 1(7954):292-6. PubMed ID: 55599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [L-dopa therapy of parkinson syndrome].
    Kapfhammer HP; Kuss HJ; Rüther E
    Nervenarzt; 1985 Feb; 56(2):57-68. PubMed ID: 3920542
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacokinetics of levodopa and motor fluctuations.
    Hardie RJ; Lees AJ; Stern GM
    Adv Neurol; 1987; 45():487-92. PubMed ID: 3825728
    [No Abstract]   [Full Text] [Related]  

  • 8. Levodopa pharmacokinetics and dyskinesias: are there sex-related differences?
    Martinelli P; Contin M; Scaglione C; Riva R; Albani F; Baruzzi A
    Neurol Sci; 2003 Oct; 24(3):192-3. PubMed ID: 14598082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Experience with a l-dopa retard preparation in the peroral long-term therapy of the Parkinsonian syndrome].
    Binder H; Gerstenbrand F; Grünberger J; Gründig E; Schubert H
    Nervenarzt; 1976 Nov; 47(11):656-60. PubMed ID: 826840
    [No Abstract]   [Full Text] [Related]  

  • 10. [Controlled release levodopa-benserazide and changes in efficacy during treatment of Parkinson's disease].
    Rondot P; Ziegler M; Aymard N; Holzer J
    Rev Neurol (Paris); 1987; 143(11):746-52. PubMed ID: 3324265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and pharmacodynamics of levodopa.
    Nutt JG
    Mov Disord; 2008; 23 Suppl 3():S580-4. PubMed ID: 18781675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does tolerance develop to levodopa? Comparison of 2- and 21-H levodopa infusions.
    Nutt JG; Carter JH; Woodward W; Hammerstad JP; Gancher ST
    Mov Disord; 1993 Apr; 8(2):139-43. PubMed ID: 8474479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Controlled-release levodopa/carbidopa. III: Sinemet CR5 treatment of response fluctuations in Parkinson's disease.
    Cedarbaum JM; Hoey M; Kutt H; McDowell FH
    Clin Neuropharmacol; 1988 Apr; 11(2):168-73. PubMed ID: 3378225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Long-term problems of levodopa therapy in Parkinson disease].
    Albani C; Asper R; Baumgartner G
    Schweiz Med Wochenschr; 1987 Mar; 117(10):347-53. PubMed ID: 3105050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The effect of controlled release of DOPA and carbidopa on clinical response and plasma pharmacokinetics of DOPA in parkinsonian patients].
    García de Yébenes J; Mateo D; Pino MA; Cordero M; Pastor M; Chacón J; Morales B; Sánchez V; Mena MA; Giménez Roldán S
    Neurologia; 1997 Apr; 12(4):145-56. PubMed ID: 9235023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Individual levodopa therapy in Parkinson's disease.
    Albani C; Asper R; Hacisalihzade SS; Baumgartner G
    Adv Neurol; 1987; 45():497-501. PubMed ID: 3825729
    [No Abstract]   [Full Text] [Related]  

  • 17. [Complications of long-term levodopa therapy in Parkinson's disease].
    Kostić V; Nikolić M
    Srp Arh Celok Lek; 1984 Sep; 112(9):975-84. PubMed ID: 6531729
    [No Abstract]   [Full Text] [Related]  

  • 18. Dystonia and Parkinson's disease.
    Carella F; Giovannini P; Girotti F; Testa D; Caraceni T
    Adv Neurol; 1993; 60():558-61. PubMed ID: 8420191
    [No Abstract]   [Full Text] [Related]  

  • 19. Single-dose study of slow release preparation of levodopa and benserazide (Madopar HBS) in Parkinson's disease.
    Marion MH; Stocchi F; Quinn NP; Jenner P; Marsden CD
    Adv Neurol; 1987; 45():493-6. PubMed ID: 3548262
    [No Abstract]   [Full Text] [Related]  

  • 20. New and emerging strategies for improving levodopa treatment.
    Tolosa ES; Valldeoriola F; Martí MJ
    Neurology; 1994 Jul; 44(7 Suppl 6):S35-44. PubMed ID: 8047259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.